Shots:

• The US FDA has approved Janssen’s Darzalex + Amgen’s Kyprolis (carfilzomib) and dexamethasone (DKd)  in two dosing regimen (70 mg/m² - qw and 56 mg/m² - q2w) for the treatment of adult patients with r/r MM who have received 1-3L therapies
• The approval of q2w dosing regimen is based on P-III CANDOR study assessing DKd (q2w) vs Kd in 466 patients with r/r MM and has met its 1EPs of PFS after a median follow-up of 16.9 & 16.3 mos. respectively
• The inclusion of carfilzomib (qw) as an approved DKd regimen is based P-Ib EQUULEUS study assessing Darzalex in combination with multiple treatment regimens. Carfilzomib (qw) was evaluated with a starting dose of 20 mg/m²- which was increased to 70 mg/m² on Cycle 1- Day 8 and onward

Source 1- Source 2 ­ Ref: Janssen- Amgen  | Image: Revlimid